Dopaminergic Immunofluorescence Studies in Kidney Tissue ............. 151

AuguSto c. moNtezANo • British Heart Foundation Glasgow Cardiovascular Research

Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow,

Glasgow, UK WilliAm mulleN • School of Natural Sciences, University of Stirling, Stirling, UK KArlA b. NeveS • British Heart Foundation Glasgow Cardiovascular Research Centre,

Institute of Cardiovascular and Medical Sciences, University of Glasgow,

Glasgow, UK pAul oleyNiK • Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada SANdoSh pAdmANAbhAN • BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK pierre pArAdiS • Lady Davis Institute for Medical Research, Jewish General Hospital,

McGill University, Montreal, QC, Canada Kim briNt pederSeN • Department of Pharmacology and Experimental Therapeutics and

Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center,

New Orleans, LA, USA yohANN rAutureAu • Lady Davis Institute for Medical Research, Jewish General Hospital,

McGill University, Montreal, QC, Canada frANciSco J. rioS • British Heart Foundation Glasgow Cardiovascular Research Centre,

Institute of Cardiovascular and Medical Sciences, University of Glasgow,

Glasgow, UK robSoN A.S. SANtoS • National Institute of Science and Technology in

Nanobiopharmaceutics, Federal University of Minas, Gerais, Brazil Department of Physiology and Biophysics, Biological Science Institute, Federal University of Minas, Gerais, Brazil viNceNt SAuzeAu • INSERM, UMR_S1087-CNRS UMR_C6291, Nantes,

France; Université de Nantes, Nantes, France; CHU de Nantes, l’institut du thorax,

Nantes, France erNeSto l. SchiffriN • Lady Davis Institute for Medical Research and Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada chriStiN Schulz • BHF Glasgow Cardiovascular Research Centre, Institute of

Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK r.e. vAN Sciver • Department of Mircobiology and Molecular Cell Biology, Eastern

Virginia Medical School, Norfolk, Virginia SimoN yANicK • Department of Anatomy and Cell Biology, Faculty of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada curt d. SigmuNd • Department of Pharmacology, Roy J . and Lucille A . Carver College of Medicine, University of Iowa, Iowa City, IA, USA SriNivAS SrirAmulA • Department of Pharmacology and Experimental Therapeutics and Cardiovascular Center of Excellence, Louisiana State University Health Sciences

Center, New Orleans, LA, USA mihAil todirAS • Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany rhiAN. m. touyz • Kidney Research Centre, Department of Medicine, Ottawa Hospital

Research Institute, University of Ottawa, Ottawa, ON, Canada BHF Glasgow Cardiovascular Research Centre, Canada and Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK SofiA tSiropoulou • Institute of Cardiovascular and Medical Sciences, BHF Glasgow

Cardiovascular Research Centre, University of Glasgow, Glasgow, UK